SRR11296848
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- CHOLESTEROL_HOMEOSTASIS+0.310
- MYC_TARGETS_V2+0.270
- MYC_TARGETS_V1+0.260
- FATTY_ACID_METABOLISM+0.230
- INTERFERON_ALPHA_RESPONSE+0.220
- ADIPOGENESIS+0.210
- MTORC1_SIGNALING+0.180
- INTERFERON_GAMMA_RESPONSE+0.150
Top 10 suppressed
- UV_RESPONSE_DN-0.400
- TGF_BETA_SIGNALING-0.390
- PROTEIN_SECRETION-0.380
- MITOTIC_SPINDLE-0.320
- HEDGEHOG_SIGNALING-0.180
- KRAS_SIGNALING_UP-0.180
- IL2_STAT5_SIGNALING-0.170
- WNT_BETA_CATENIN_SIGNALING-0.160
- NOTCH_SIGNALING-0.130
- ANDROGEN_RESPONSE-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-UU-A93S-01A-21R-A41B-07 | — | C | 0.845 |
| 2 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.826 |
| 3 | TCGA-E2-A9RU-01A-11R-A41B-07 | — | B | 0.807 |
| 4 | TCGA-GM-A2DB-01A-31R-A18M-07 | — | C | 0.799 |
| 5 | MNG263 | — | — | 0.797 |
| 6 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.790 |
| 7 | TCGA-38-4631-01A-01R-1755-07 | — | cohortA4 | 0.789 |
| 8 | SRR25617935 | — | E | 0.778 |
| 9 | a8cd01e2-f7f4-487c-8cde-4fcf21bfe0e7 | — | — | 0.770 |
| 10 | TCGA-OR-A5JE-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |